British drugmaker AstraZeneca said Monday it has started Phase 3 trials of its experimental coronavirus vaccine in the United States, becoming the third company to start late-stage trials of a Covid-19 vaccine.
The vaccine, developed in partnership with Oxford University, has the backing of the US federal government. Rivals Moderna and Pfizer/BioNTec already have Phase 3 trials under way, also with federal government funding.
AstraZeneca said it is "recruiting up to 30,000 adults aged 18 years or over from diverse racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions, including those living with HIV, and who are at increased risk of infection from the SARS-CoV-2 virus."
Participants will receive two active or placebo doses, spaced four weeks apart. Currently, Phase 3 trials of AstraZeneca's vaccine are going on in Britain, Brazil and South Africa. Trials are also planned for Japan and Russia.
AstraZeneca says it intends to enroll more than 50,000 volunteers globally, including 30,000 in the US, as well as participants in Latin America, Asia, Europe and Africa.
Read the full story: